optum cdm data (Optum Inc)
86
Structured Review
Optum Inc
optum cdm data
Optum Cdm Data, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum+cdm+data/cdm+optum/pm42296834-252-16-16
Average 86 stars, based on 1 article reviews
Optum Cdm Data, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum+cdm+data/cdm+optum/pm42296834-252-16-16
Average 86 stars, based on 1 article reviews
optum cdm data - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
other:Article Title: Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study Article Snippet: This study leveraged Novo Nordisk’s license of Article Title: Comorbidity and comedication burden in people living with HIV in the United States: updated findings from a contemporary cohort (2020-2024). Article Snippet: Objective: To describe comorbidity and comedication burden among people living with HHIV(PLWH) compared with matched people without HIV and evaluate 5-year trends among PLWH from 2020–2024.. Methods: This retrospective study used administrative claims data (01/01/2016–01/31/2025) from Optum’s de-identified Clinformatics Data Mart Database.. The PLWH cohort included adults with �1 medical or pharmacy claim for an antiretroviral therapy (ART) agent in 2024 or, for those not treated with ART, an HIV diagnosis code alone (index date: earliest ART or HIV claim). Article Title: Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study. Article Snippet: This study leveraged Novo Nordisk’s license of Article Title: Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023. Article Snippet: Background: Background incidence rates (IRs) of safety outcomes in the absence of vaccination of interest and IRs following the infection targeted by the vaccine, are integral for contextualizing vaccine benefit-risk.. As new respiratory vaccines are developed, contemporaneous IR estimates for outcomes commonly assessed in vaccine safety surveillance are needed in the COVID-19 endemic era.. Methods: This retrospective cohort study used four administrative claims data sources in the United States (HealthVerity Closed Claims, Optum's de-identified Clinformatics® Data Mart, Humana and Medicare Fee-ForService) to estimate IRs for 30 safety outcomes across five organ systems between 1 August 2022 and 31 July 2023. Article Title: Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors. Article Snippet: Objective: To estimate the comparative effectiveness of first-line (1 L) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK-positive non-small cell lung cancer (NSCLC) in the United States.. Methods: We conducted a retrospective cohort study using Optum’s de-identified Clinformatics® Data Mart Database (2016–2024).. Patients with lung cancer ICD-10 codes and pharmacy claims for ALK TKIs were eligible if aged ≥ 18 years, continuously enrolled ≥ 6 months before initiation, and treated after each drug’s FDA approval. Article Title: Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012–2023: A US Cohort Study Article Snippet: Article Title: Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States Article Snippet: The proportion of patients on treatment with finerenone at the 12-month mark is broadly consistent with 12-month persistence rates observed for |